Category Archives: Pr Newswire

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA’s common stock, payable on August 28, 2024, to ARCA’s stockholders of record as of […]

Major Joint Venture Awarded Consultancy Agreement of San Tin Technopole

Development bolsters housing supply, cultivates job opportunities and revitalizes community DALLAS, Aug. 27, 2024 /PRNewswire/ — Halcrow, a Jacobs-owned company and AECOM Joint Venture has secured a consultancy agreement with the Civil Engineering and Development Department (CEDD) for the first phase of the San Tin Technopole in Hong Kong. The development is one of the […]

Telix Announces Reorganisation to Deliver on Strategic Priorities

MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.  The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), […]

Kaiyi Healthcare: Pioneering Medical Innovation, Deepening Brand Essence, and Shaping a Healthier Future Together

SHANGHAI, Aug. 27, 2024 /PRNewswire/ — Recently, Kaiyi Healthcare has made significant strides across its network of hospitals. In July, Wuxi Kaiyi Hospital launched a new emergency response substation connected to China’s ‘120’ emergency medical services (EMS)—a system akin to ‘911’ in the US or ‘999’ in the UK—within its facilities. In August, Jiaxing Kaiyi Hospital […]

Iconic Australian Athletic Brand 2XU Partners with Pattern for International Repositioning

Pattern Supports 2XU to Transform Brand Perception, Boosting Average Selling Price by 25% MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ — Leading global ecommerce and marketplace accelerator, Pattern, today announced it has supported iconic Australian athletic wear brand 2XU to pivot its international business, solidifying its position as a leading specialist technical athletic brand in key markets, including North […]

Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI’s $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) […]

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

– The TRACE-AI Network Study will deploy a scalable screening toolkit for ATTR-CM across large, diverse health system electronic health records (EHRs) aiming to identify individuals who have ATTR-CM earlier in their disease course and quantify the potential prevalence of undiagnosed ATTR-CM PALO ALTO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) […]

Kraig Biocraft Laboratories Significantly Increases Spider Silk Reeling Efficiency, Boosting Per Cocoon Yield

ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has further boosted spider silk production with the introduction of new silk cocoon reeling protocols resulting in higher silk yields. Under the guidance of renowned sericulture expert, Dr. Nirmal Kumar, the […]

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT (pronounced “limelight”) clinical trial in Canada. […]